Lower Gastrointestinal Cancers

2013 ◽  
pp. 209-231
Author(s):  
Sravana Chennupati ◽  
Celine Bicquart Ord ◽  
Charles R. Thomas
Keyword(s):  
Gastrointestinal Cancers

ASCO-GI 2019: Gallengangskarzinome

2019 ◽  
Vol 10 (02) ◽  
pp. 67-67
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Los Angeles ◽  
Phase Ii ◽  
Gastrointestinal Cancers

Gallengangskarzinome treten selten auf und weisen eine sehr schlechte Prognose auf. In einer auf dem Gastrointestinal Cancers Symposium (GICS) vorgestellten offenen Phase-II-Studie führte die Kombination der BRAF- and MEK-Inhibitoren Dabrafenib und Trametinib zu einer objektiven Responserate (ORR) als primärem Endpunkt von 41 % (13/32; 95 % Konfidenzintervall [KI] 24–59 %), so Prof. Zev A. Wainberg, Los Angeles/USA.

ASCO-GI 2019: Pankreaskarzinom

2019 ◽  
Vol 10 (02) ◽  
pp. 60-61
Author(s):  
Ine Schmale
Keyword(s):  
Gastrointestinal Cancers

Während bei vielen Tumorentitäten große Fortschritte in der Behandlung zu berichten sind, bleibt das Pankreaskarzinom ein Tumor mit einer schlechten Prognose und wenigen Therapieoptionen. Beim Gastrointestinal Cancers Symposium (ASCO­GI) wurde eine Sitzung der frühen Detektion, der Sequenztherapie resektabler Tumoren und den Therapien der Zukunft beim Pankreaskarzinom gewidmet.

Adoptive Cell Therapy for Gastrointestinal Cancers

2020 ◽  
Vol 04 (04) ◽  
pp. 345-350
Author(s):  
Ryan J. Slovak ◽  
Hyun S. Kim
Keyword(s):  
Cell Therapy ◽  
Clinical Research ◽  
Solid Tumors ◽  
Immune Cells ◽  
Ex Vivo ◽  
Adoptive Cell Therapy ◽  
Hematologic Malignancies ◽  
Gastrointestinal Cancers ◽  
Gastrointestinal Malignancies ◽  
Specific Antigens

AbstractThe reinfusion of autologous or allogeneic immune cells that have been educated and/or engineered ex vivo to respond to tumor-specific antigens is termed “adoptive cell therapy.” While adoptive cell therapy has made tremendous strides in the treatment of hematologic malignancies, its utilization for solid tumors has lagged somewhat behind. The purpose of this article is to concisely review the clinical research that has been done to investigate adoptive cell therapy as a treatment for gastrointestinal malignancies.

Endoscopic submucosal dissection by using Clutch cutter and IT knife 2 for early gastric cancer with severe submucosal fibrosis: a case report

MedPharmRes ◽  
2018 ◽  
Vol 2 (3) ◽  
pp. 17-21
Author(s):  
Nhan Le ◽  
Phuong Vien ◽  
Nghia Le
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Endoscopic Submucosal Dissection ◽  
Narrow Band ◽  
Narrow Band Imaging ◽  
Magnifying Endoscopy ◽  
Gastrointestinal Cancers ◽  
Pathological Result ◽  
Well Differentiated ◽  
Submucosal Fibrosis

Introduction: Gastric cancer is one of the highly malignant gastrointestinal cancers and the third leading cause of cancer death. In the last decade, early gastric cancer (EGC) has been reported by using narrow-band imaging (NBI) magnifying endoscopy. Advances in endoscopic techniques, such as endoscopic submucosal dissection (ESD), have enabled the en bloc resection of these EGC. Although ESD is performed for early gastric cancer, there are still many difficult problems in technique of this procedure. The difficulty of gastric ESD depends on the size and location of a tumor, presence of severe submucosal fibrosis, presence of ulceration... We report a case of our successful ESD by using Clutch cutter and IT knife 2 in treatment of EGC with severe submucosal fibrosis. Case presentation: A 62-year-old man felt an epigastric discomfort two months ago. The narrow-band imaging (NBI) magnifying endoscopy revealed a suspected early gastric cancer type 0 - IIa + IIc (Japanese classification of early gastrointestinal cancers) at the incisura angularis, the size of this lesion was 15 mm in diameter, and pathological result of endoscopic biopsy was a well-differentiated adenocarcinoma. ESD was performed and we found there was severe submucosal fibrosis which was dissected safer and faster by using Clutch cutter and IT knife 2. There were no complications such as severe bleeding and perforation. The size of resected specimen was 60 x 35 mm and the time of procedure was 150 minutes. After ESD, the pathological result was a well differentiated adenocarcinoma, pT1a, UL(-), LY(-), V(-), no cancer cell in vertical and horizontal margins. The healing time of ESD-induced ulcer was 5 weeks without local recurrence. Conclusion: Through this case, we aim to emphasize the importance of using Clutch cutter and IT knife 2 as a modified technique which makes ESD a safe procedure in treatment of EGC with severe submucosal fibrosis.

Preliminary Results of the use of Self-Expanding Nitinol Stents in Inoperable Gastrointestinal Cancers

2010 ◽  
Vol 82 (5) ◽  
Author(s):  
Tomasz Miłek ◽  
Piotr Ciostek ◽  
Witold Woźniak ◽  
Andrzej Lewczuk ◽  
Robert Petryka ◽  
...  
Keyword(s):  
Use Of Self ◽  
Gastrointestinal Cancers ◽  
Preliminary Results ◽  
Nitinol Stents

Management of Common Gastrointestinal Cancers During the COVID-19 Pandemic - Volume Indicators and Case Fatality Rates from LMICs as a Basis for Cancer Care Policy

2020 ◽  
Author(s):  
Vikas S. Ostwal ◽  
Prabhat Bhargava ◽  
Sujay Srinivas ◽  
Sarika Mandavkar ◽  
Poonam Jadhav ◽  
...  
Keyword(s):  
Cancer Care ◽  
Case Fatality ◽  
Gastrointestinal Cancers ◽  
Care Policy

Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress

2014 ◽  
Vol 15 (14) ◽  
pp. 1302-1311 ◽  
Author(s):  
Sharareh Gholamin ◽  
Hamid Fiuji ◽  
Mina Maftouh ◽  
Reza Mirhafez ◽  
Fatemeh Shandiz ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Gastrointestinal Cancers ◽  
Upper Gastrointestinal
Sign in / Sign up

Export Citation Format

Share Document